Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy

Clinical and Experimental Allergy

Volumn 42, Issue 6, 2012, Pages 966-975

  Twaroch, T E ^a   Focke, M ^a   Fleischmann, K ^a   Balic, N ^b   Lupinek, C ^b   Blatt, K ^a   Ferrara, R ^c   Mari, A ^c   Ebner, C ^d   Valent, P ^a   Spitzauer, S ^b   Swoboda, I ^a   Valenta, R ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Pathophysiology and Allergy Research   (Austria)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d Allergy Clinic Reumannplatz   (Austria)

Author keywords

Allergen; Alt a 1; Alternaria alternata; Diagnosis; Peptides; Specific immunotherapy

Indexed keywords

ALLERGEN; ALT A 1 PROTEIN; CARRIER PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT ALT A 1 PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLERGY; ALLERGY TEST; ALTERNARIA ALTERNATA; ALTERNARIA ALTERNATA ALLERGY; ARTICLE; AUSTRIA; BASOPHIL; CELL ACTIVATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GROWTH INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHERAPY; ITALY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MULTICENTER STUDY; MYCOSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RABBIT; SENSITIZATION; SERUM; SPECIFIC IMMUNOTHERAPY;

ADOLESCENT; ADULT; ALTERNARIA; ANIMALS; ANTIBODIES, FUNGAL; ANTIBODY SPECIFICITY; ANTIGENS, FUNGAL; CHILD; FEMALE; FUNGAL VACCINES; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; PEPTIDES; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; RABBITS; YOUNG ADULT;

EID: 84864309655     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2012.03996.x     Document Type: Article

References (43)

1. Kurup VP, Shen HD, Vijay H. Immunobiology of fungal allergens. Int Arch Allergy Immunol 2002; 129:181-8.
2. Simon-Nobbe B, Denk U, Pöll V, Rid R, Breitenbach M. The spectrum of fungal allergy. Int Arch Allergy Immunol 2008; 145:58-86.
3. D'Amato G, Chatzigeorgiou G, Corsico R et al. Evaluation of the prevalence of skin prick test positivity to Alternaria and Cladosporium in patients with suspected respiratory allergy. A European multicenter study promoted by the Subcommittee on Aerobiology and Environmental Aspects of Inhalant Allergens of the European Academy of Allergology and Clinical Immunology Allergy 1997; 52:711-6.
4. Zureik M, Neukirch C, Leynaert B, Liard R, Bousquet J, Neukirch F. European Community Respiratory Health Survey. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ 2002; 325:411-4.
5. Salo PM, Arbes SJ Jr, Sever M et al. Exposure to Alternaria alternata in US homes is associated with asthma symptoms. J Allergy Clin Immunol 2006; 118:892-8.
6. Sanchez H, Bush RK. A review of Alternaria alternata sensitivity. Rev Iberoam Micol 2001; 18:56-9.
7. Neukirch C, Henry C, Leynaert B, Liard R, Bousquet J, Neukirch F. Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study. J Allergy Clin Immunol 1999; 103:709-11.
8. D'Amato G, Spieksma FT. Aerobiologic and clinical aspects of mould allergy in Europe. Allergy 1995; 50:870-7.
9. Salo PM, Yin M, Arbes SJ Jr et al. Dustborne Alternaria alternata antigens in US homes: results from the National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol 2005; 116:623-9.
10. Mari A, Schneider P, Wally V, Breitenbach M, Simon-Nobbe B. Sensitization to fungi: epidemiology, comparative skin tests, and IgE reactivity of fungal extracts. Clin Exp Allergy 2003; 33:1429-38.
11. Helbling A, Reimers A. Immunotherapy in fungal allergy. Curr Allergy Asthma Rep 2003; 3:447-53.
12. Vailes L, Sridhara S, Cromwell O, Weber B, Breitenbach M, Chapman M. Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products. J Allergy Clin Immunol 2001; 107:641-6.
13. Ibarrola I, Suárez-Cervera M, Arilla MC et al. Production profile of the major allergen Alt a 1 in Alternaria alternata cultures. Ann Allergy Asthma Immunol 2004; 93:589-93.
14. Martínez J, Gutiérrez A, Postigo I, Cardona G, Guisantes J. Variability of Alt a 1 expression by different strains of Alternaria alternata. J Investig Allergol Clin Immunol 2006; 16:279-82.
15. Sáenz-de-Santamaría M, Guisantes JA, Martínez J. Enzymatic activities of Alternaria alternata allergenic extracts and its major allergen (Alt a 1). Mycoses 2006; 49:288-92.
16. Rid R, Onder K, MacDonald S et al. Alternaria alternata TCTP, a novel cross-reactive ascomycete allergen. Mol Immunol 2009; 46:3476-87.
17. Asturias JA, Ibarrola I, Ferrer A et al. Diagnosis of Alternaria alternata sensitization with natural and recombinant Alt a 1 allergens. J Allergy Clin Immunol 2005; 115:1210-7.
18. Postigo I, Gutiérrez-Rodríguez A, Fernández J, Guisantes JA, Suñén E, Martínez J. Diagnostic value of Alt a 1, fungal enolase and manganesedependent superoxide dismutase in the component-resolved diagnosis of allergy to pleosporaceae. Clin Exp Allergy 2011; 41:443-51.
19. De Vouge MW, Thaker AJ, Curran IH et al. Isolation and expression of a cDNA clone encoding an Alternaria alternata Alt a 1 subunit. Int Arch Allergy Immunol 1996; 111:385-95.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
21. Focke M, Mahler V, Ball T et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001; 15:2042-4.
22. Twaroch TE, Focke M, Civaj V et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol 2011; 128:178-84.
23. Hauswirth AW, Natter S, Ghannadan M et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002; 110:102-9.
24. Siskind GW, Paul WE, Benacerraf B. Studies on the effect of the carrier molecule on antihapten antibody synthesis I. Effect of carrier on the nature of the antibody synthesized. J Exp Med 1966; 123:673-88.
25. Paul WE, Katz DH, Goidl EA, Benacerraf B. Carrier function in anti-hapten immune responses II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med 1970; 132:283-99.
26. Leino M, Reijula K, Mäkinen-Kiljunen S, Haahtela T, Mäkelä MJ, Alenius H. Cladosporium herbarum and Pityrosporum ovale allergen extracts share cross-reacting glycoproteins. Int Arch Allergy Immunol 2006; 140:30-5.
27. Zhang L, Curran IH, Muradia G, De VougeMW, Rode H, Vijay HM. N-terminus of a major allergen, Alt a I, of Alternaria alternata defined to be an epitope. Int Arch Allergy Immunol 1995; 108:254-9.
28. Kurup VP, Vijay HM, Kumar V, Castillo L, Elms N. IgE binding synthetic peptides of Alt a 1, a major allergen of Alternaria alternata. Peptides 2003; 24:179-85.
29. Ball T, Vrtala S, Sperr WR et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994; 269:28323-8.
30. Westritschnig K, Horak F, Swoboda I et al. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur J Clin Invest 2008; 38: 260-7.
31. Twaroch TE, Arcalís E, Sterflinger K, Stöger E, Swoboda I, Valenta R. Predominant localization of the major Alternaria allergen Alt a 1 in the cell wall of airborne spores. J Allergy Clin Immunol 2011; PMID:22078468 [Epub ahead of print].
32. Arnon R, Van Regenmortel MH. Structural basis of antigenic specificity and design of new vaccines. FASEB J 1992; 6:3265-74.
33. Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 1999; 30:597-623.
34. Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000; 6:1693-701.
35. Demoly P, Persi L, Dhivert H, Delire M, Bousquet J. Immunotherapy with keyhole limpet hemocyanin-conjugated decapeptide vaccine in cypress pollen allergy. Clin Exp Allergy 2002; 32:1071-6.
36. Edlmayr J, Niespodziana K, Linhart B et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009; 182:6298- 306.
37. Niespodziana K, Focke-Tejkl M, Linhart B et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011; 127:1562-70.
38. Fedorov AA, Ball T, Mahoney NM, Valenta R, Almo SC. The molecular basis for allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen profilin. Structure 1997; 5:33-45.
39. Flicker S, Steinberger P, Ball T et al. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. J Allergy Clin Immunol 2006; 117:1336-43.
40. Padavattan S, Flicker S, Schirmer T et al. High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J Immunol 2009; 182:2141-51.
41. Flicker S, Vrtala S, Steinberger P et al. A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain. J Immunol 2000; 165:3849-59.
42. Gieras A, Cejka P, Blatt K et al. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol 2011; 186:5333-44.
43. Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:951-60.